Deals channel feed – Endpoints News

Deals channel feed

Roche strikes neuro-focused partnership with RNA exon editing startup, worth as much as $1.8B

11 months ago

As it deepens immunology bets, Sanofi inks small molecule pact with Belharra

11 months ago

J&J returns bispecific T cell engager to Xencor, reducing scope of partnership

11 months ago

AbbVie banks on second-gen TL1A program, licensing antibody from FutureGen

11 months ago

Gilead's M&A appetite is for deals in the 'mid-single-digit billions,' CEO says

11 months ago

Pfizer strikes an R&D partnership with Flagship's ProFound as it looks for next-gen obesity assets

11 months ago

GSK nixes SpringWorks licensing deal focused on Blenrep-Ogsiveo for blood cancer

11 months ago

Ipsen returns to Marengo Therapeutics for new trispecific deal

11 months ago

J&J’s dealmaker: Plenty of ‘firepower,’ but mostly focused on tuck-in M&A

11 months ago

GSK acquires tiny RNA startup Elsie, boosting its grand plans for developing RNA drugs

11 months ago

To pay off debt and stay open, Seres will sell microbiome pill to partner Nestlé

11 months ago

Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows

11 months ago

Merck KGaA continues AI drug discovery deal spree with Biolojic Design

11 months ago

Illumina board agrees to spin off Grail rather than sell the cancer diagnostics firm

12 months ago

Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia

12 months ago

Adaptimmune taps Galapagos to decentralize manufacturing of solid tumor T cell therapy

12 months ago

Exclusive: Plenful nabs $17M to automate pharmacy operations

12 months ago

Company developing video games for ADHD announces sale

Last year

Bristol Myers pays $80M to license another Prothena neuroscience candidate

Last year

Merck returns to lucrative eye disease market in up to $3B deal for EyeBio

Last year

J&J makes another I&I acquisition with $1.25B deal for Numab's Yellow Jersey

Last year

Gilead forms pact with Cartography to map new targets for cancer drugs

Last year

Calliditas’ rare disease drug draws $1B+ buyout offer from Japanese buyer

Last year

BioNTech doubles down on ADC partner MediLink in new $1.8B biobucks pact

Last year

First page Previous page 14 15 161718 19 20 Next page Last page